YM155
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Large-Cell, Diffuse
Conditions
Lymphoma, Large-Cell, Diffuse, Lymphoma, B-Cell Refractory
Trial Timeline
Jun 1, 2007 → Apr 1, 2009
NCT ID
NCT00498914About YM155
YM155 is a phase 2 stage product being developed by Astellas Pharma for Lymphoma, Large-Cell, Diffuse. The current trial status is terminated. This product is registered under clinical trial identifier NCT00498914. Target conditions include Lymphoma, Large-Cell, Diffuse, Lymphoma, B-Cell Refractory.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, Large-Cell, Diffuse were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00257478 | Phase 2 | Completed |
| NCT01023386 | Phase 1 | Completed |
| NCT00498914 | Phase 2 | Terminated |
| NCT00328588 | Phase 2 | Completed |
| NCT00818480 | Phase 2 | Completed |
| NCT00281541 | Phase 2 | Completed |
Competing Products
20 competing products in Lymphoma, Large-Cell, Diffuse